open access

Vol 72, No 6 (2021)
Editorial
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-12-30
Get Citation

Flozins — in the light of the latest recommendations

Marta Wróbel1, Dominika Rokicka1, Krzysztof Strojek1
DOI: 10.5603/EP.a2021.0098
·
Pubmed: 34970990
·
Endokrynol Pol 2021;72(6):589-591.
Affiliations
  1. Department of Internal Medicine, Diabetology, and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland

open access

Vol 72, No 6 (2021)
Editorial
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-12-30

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Flozins — in the light of the latest recommendations

Journal

Endokrynologia Polska

Issue

Vol 72, No 6 (2021)

Article type

Editorial

Pages

589-591

Published online

2021-12-30

Page views

1342

Article views/downloads

233

DOI

10.5603/EP.a2021.0098

Pubmed

34970990

Bibliographic record

Endokrynol Pol 2021;72(6):589-591.

Authors

Marta Wróbel
Dominika Rokicka
Krzysztof Strojek

References (16)
  1. Sieradzki J. Cukrzyca. Via Medica, Gdańsk 2019.
  2. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  3. Wiviott S, Raz I, Bonaca M, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New Engl J Med. 2019; 380(4): 347–357.
  4. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7): 644–657.
  5. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
  6. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24): 2295–2306.
  7. Packer M, Butler J, Filippatos G, et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. Eur J Heart Fail. 2019; 21(10): 1270–1278.
  8. Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 [Epub ahead of print].
  9. Mason T, Coelho-Filho O, Verma S, et al. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC: Cardiovasc Imag. 2021; 14(6): 1164–1173.
  10. Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci (Lond). 2018; 132(12): 1329–1339.
  11. Heerspink HJL, Stefansson BV, Chertow GM, et al. DAPA-CKD Investigators. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35(2): 274–282.
  12. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  13. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(2): 487–493.
  14. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clin Diabetol. 2021; 10(1).
  15. Seferović P, Coats A, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. Eur J Heart Fail. 2020; 22(2): 196–213.
  16. Karagiannis T, Tsapas A, Bekiari E. KDIGO made 12 recommendations for managing diabetes with CKD. Ann Int Med. 2021; 174(3): JC26.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl